In the EMPEROR-Preserved trial (43), a sodium-glucose cotransporter-2 inhibitor (SGLT-2i; empagliflozin) reduced the risk of composite cardiovascular death or total HF hospitalization by 21% in patients with HF with LVEF > 40%, driven primarily by a significant reduction in the HF hospitalization of 29% (no significant reduction in cardiovascular death [hazard ratio (HR), 0.91; 95% CI: 0.76–1.0]), with no benefit for all-cause mortality. The gene discussed is SLC5A2; the disease is hydrops fetalis.